What We Do:

Spatially Fractionated Radiation Treatment (SFRT)

Spatially Fractionated Radiation Therapy (SFRT) is a radiation therapy technique that allows for safe dose escalation for radiation for radiation treatment. Specialized beam collimation creates high-dose peaks organized throughout a target volume with intervening low-dose valleys. Pre-clinical animal studies have shown that with a single dose of SFRT there is much lower toxicity, good tumor control, and employs the patients own immunity to fight the tumor/cancer.

NuVeta will deliver beams 0.5mm thin. This will allow NuVeta to harvest all the benefits of safe SFRT that would be consistent with the previous animal studies and repeat the same results in humans.

Conceptual SFRT

Spatially Fractionated Radiation Treatment (SFRT)

Current Problems:

Unmet Needs of Later Stage Patients

  • Large late-stage tumors
  • Tumor recurrence
  • Treatment resistant tumors

Our Solution:

Drastically Reduce the Level of Radiation Therapy Toxicity

Pre-clinical animal studies have shown that with a single dose of RT there is much lower toxicity, good tumor control, and it employs the patient’s own immunity to fight the tumor/cancer. Pre-clinical SFRT data shows the tissue sparing MRT radiation is tumor controlling.

Current attempts to employ SFRT, utilizing traditional radiation machines still experience radiation beams being too broad. Current SFRT radiation beams are too broad/wide at 10-20mm, creating too much damage with a large radiation footprint. NuVeta will deliver beams 0.5mm thin. This will allow NuVeta to fully harvest all the benefits of safe SFRT that would be consistent with the previous animal studies and repeat the same results in humans.

The Team:

Who We Are

At NuVeta Radiotherapy, we have a strong management team and scientific board composed of individuals who have a wide range of skills and experience. With strong leadership in place, we are well positioned to achieve our goals and drive the success of the company.

Management Team

Walid Mustafa

Chief Executive Officer

Dr. Sha Chang

Chief Scientific Officer &
Scientific Advisory Board Member

Dr. Jerry Zhang

Chief Technology Officer &
Scientific Advisory Board Member

Dr. Chen Quian

Chief Nano Technology Officer

Phillip Wise

Chief Financial Officer

General David L. Grange

VP of Business Development

Dr. Michael Harris

Chief Medical Officer &
Secretary to the Scientific Advisory Board

Valentin Djonov

Scientific Advisory Board

Sha Chang - UNC

PhD, FAAPM

Mark W. Dewhirst - Duke

DVM, PhD

William C. Zamboni - UNC

PharmD, PhD

Majid Mohiuddin - Chicago

M.D.

Dr. Jerry Zhang

Chief Technology Officer

Michael P. Grams - Mayo Clinic

Ph.D.

Valentin Djonov - University of Berne, Switzerland

M.D.

Contact Us:

Have questions, or want to learn more?

Sign Up to Get More Information: